Switching to riociguat versus maintenance therapy with phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension (REPLACE): a multicentre, open-label, randomised controlled trial

里奥西瓜特 医学 cGMP特异性磷酸二酯酶5型 西地那非 打开标签 肺动脉高压 内科学 抢救疗法 随机对照试验 心脏病学 重症监护医学 慢性血栓栓塞性肺高压
作者
Marius M. Hoeper,Hikmet Al‐Hiti,Raymond L. Benza,Sung‐A Chang,Paul A. Corris,J. Simon R. Gibbs,Ekkehard Grünig,P Jansa,James R. Klinger,David Langleben,Vallerie V. McLaughlin,G. Meyer,Jaquelina Sonoe Ota Arakaki,Andrew J. Peacock,Tomás Pulido,Stephan Rosenkranz,Carmine Dario Vizza,Anton Vonk Noordegraaf,R.J. White,Mikyung Chang
出处
期刊:The Lancet Respiratory Medicine [Elsevier BV]
卷期号:9 (6): 573-584 被引量:128
标识
DOI:10.1016/s2213-2600(20)30532-4
摘要

Riociguat and phosphodiesterase-5 inhibitors (PDE5i), approved for the treatment of pulmonary arterial hypertension (PAH), act on the same pathway via different mechanisms. Riociguat might be an alternative option for patients with PAH who do not respond sufficiently to treatment with PDE5i, but comparisons of the potential benefits of riociguat and PDE5i in these patients are needed. The aim of this trial was to assess the effects of switching to riociguat from PDE5i therapy versus continued PDE5i therapy in patients with PAH at intermediate risk of 1-year mortality.Riociguat rEplacing PDE5i therapy evaLuated Against Continued PDE5i thErapy (REPLACE) was an open-label, randomised controlled trial in 81 hospital-based pulmonary hypertension centres in 22 countries. The study enrolled patients aged 18-75 years with symptomatic PAH at intermediate risk of 1-year mortality (based on the European Society for Cardiology-European Respiratory Society guideline thresholds for WHO functional class and 6-min walk distance [6MWD]) who were receiving treatment with a PDE5i with or without an endothelin receptor antagonist for at least 6 weeks before randomisation. Patients were excluded if they had been previously treated with riociguat, had used prostacyclin analogues or prostacyclin receptor agonists within 30 days before randomisation, had clinically significant restrictive or obstructive parenchymal lung disease, or had left heart disease. Patients were randomly assigned (1:1) to remain on PDE5i treatment (oral sildenafil [≥60 mg per day] or oral tadalafil [20-40 mg per day]; the PDE5i group) or to switch to oral riociguat (up to 2·5 mg three times per day; the riociguat group), using an interactive voice and web response system, stratified by cause of PAH. The primary endpoint was clinical improvement by week 24, defined as an absence of clinical worsening and prespecified improvements in at least two of three variables (6MWD, WHO functional class, and N-terminal prohormone of brain natriuretic peptide), analysed using last observation carried forward in all randomly assigned patients with observed values at baseline and week 24 who received at least one dose of study medication (the full analysis set). Secondary endpoints included clinical worsening events. The trial has been completed and is registered with ClinicalTrials.gov, NCT02891850.Between Jan 11, 2017, and July 31, 2019, 293 patients were screened, of which 226 patients were randomly assigned to the riociguat group (n=111) or to the PDE5i group (n=115). 211 patients completed the study and 14 patients discontinued (seven in each group). One patient assigned to the PDE5i group did not receive treatment, so 225 patients were included in the safety analysis, and one further patient in the PDE5i group had missing components of the composite primary endpoint at baseline, so 224 patients were included in the full analysis set. The primary endpoint was met by 45 (41%) of 111 patients in the riociguat group and 23 (20%) of 113 patients in the PDE5i group; odds ratio [OR] 2·78 (95% CI 1·53-5·06; p=0·0007). Clinical worsening events occurred in one (1%) of 111 patients in the riociguat group (hospitalisation due to worsening PAH) and 10 (9%) of 114 patients in the PDE5i group (hospitalisation due to worsening PAH [n=9]; disease progression [n=1]; OR 0·10 [0·01-0·73]; p=0·0047). The most frequently occurring adverse events were hypotension (15 [14%]), headache (14 [13%]), and dyspepsia (10 [9%]) in the riociguat group, and headache (eight [7%]), cough (seven [6%]), and upper respiratory tract infection (seven [6%]) in the PDE5i group. Serious adverse events were reported in eight (7%) of 111 patients in the riociguat group and 19 (17%) of 114 patients in the PDE5i group. During the study, four patients died in the PDE5i group, one of them during the safety follow-up period.Switching to riociguat from PDE5i treatment, both of which act via the nitric oxide-soluble guanylate cyclase-cyclic guanosine monophosphate pathway, could be a strategic option for treatment escalation in patients with PAH at intermediate risk of 1-year mortality.Bayer AG, Merck Sharp & Dohme.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
李凌霄完成签到,获得积分10
1秒前
韦小宝发布了新的文献求助10
2秒前
2秒前
yep发布了新的文献求助10
2秒前
1Yer6完成签到 ,获得积分10
3秒前
kk发布了新的文献求助10
3秒前
李健的小迷弟应助yidong采纳,获得10
4秒前
zh发布了新的文献求助10
5秒前
量子星尘发布了新的文献求助10
5秒前
早日毕业完成签到,获得积分10
5秒前
6秒前
6秒前
桐桐应助呼之欲出采纳,获得10
6秒前
漂亮的青荷完成签到,获得积分10
9秒前
9秒前
9秒前
10秒前
小白完成签到,获得积分10
12秒前
饱满南松发布了新的文献求助10
13秒前
14秒前
无花果应助毅然决然必然采纳,获得10
14秒前
15秒前
白小白发布了新的文献求助10
16秒前
Dream发布了新的文献求助10
17秒前
17秒前
萨柏斯塔完成签到,获得积分10
18秒前
Hello应助饱满南松采纳,获得10
18秒前
SYLH应助ff采纳,获得30
19秒前
上官若男应助典雅煎蛋采纳,获得10
20秒前
will_fay发布了新的文献求助10
20秒前
21秒前
21秒前
22秒前
木炭完成签到,获得积分10
24秒前
小蘑菇应助科研通管家采纳,获得10
24秒前
搜集达人应助科研通管家采纳,获得10
24秒前
24秒前
彭于晏应助科研通管家采纳,获得10
24秒前
24秒前
24秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 700
ACSM’s Guidelines for Exercise Testing and Prescription, 12th edition 500
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
Indomethacinのヒトにおける経皮吸収 400
Phylogenetic study of the order Polydesmida (Myriapoda: Diplopoda) 370
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3975722
求助须知:如何正确求助?哪些是违规求助? 3520056
关于积分的说明 11200719
捐赠科研通 3256455
什么是DOI,文献DOI怎么找? 1798271
邀请新用户注册赠送积分活动 877490
科研通“疑难数据库(出版商)”最低求助积分说明 806390